Explore

Trendline Trendline
Byondis Appoints Christoph Korpus as CEO to Drive ADC Technology Growth

Byondis Appoints Christoph Korpus as CEO to Drive ADC Technology Growth

Byondis Appoints Christoph Korpus as CEO to Drive ADC Technology Growth
Trendline Trendline
Webinar Explores Analytical Strategies for Complex Antibody-Drug Conjugates

Webinar Explores Analytical Strategies for Complex Antibody-Drug Conjugates

Webinar Explores Analytical Strategies for Complex Antibody-Drug Conjugates
Trendline Trendline
Gilead Sciences Acquires Tubulis for $5 Billion to Enhance Cancer Treatment Capabilities

Gilead Sciences Acquires Tubulis for $5 Billion to Enhance Cancer Treatment Capabilities

Gilead Sciences Acquires Tubulis for $5 Billion to Enhance Cancer Treatment Capabilities
Trendline Trendline
Sidewinder Therapeutics Secures $137 Million to Advance Cancer Treatment

Sidewinder Therapeutics Secures $137 Million to Advance Cancer Treatment

Sidewinder Therapeutics Secures $137 Million to Advance Cancer Treatment
Trendline Trendline
Gilead Acquires Tubulis for $5 Billion to Enhance Oncology Pipeline

Gilead Acquires Tubulis for $5 Billion to Enhance Oncology Pipeline

Gilead Acquires Tubulis for $5 Billion to Enhance Oncology Pipeline
Trendline Trendline
Gilead Sciences Acquires Tubulis to Enhance Oncology Pipeline with Advanced ADC Technology

Gilead Sciences Acquires Tubulis to Enhance Oncology Pipeline with Advanced ADC Technology

Gilead Sciences Acquires Tubulis to Enhance Oncology Pipeline with Advanced ADC Technology
Trendline Trendline
Gilead to Acquire Tubulis GmbH in $5 Billion Deal to Enhance Cancer Drug Pipeline

Gilead to Acquire Tubulis GmbH in $5 Billion Deal to Enhance Cancer Drug Pipeline

Gilead to Acquire Tubulis GmbH in $5 Billion Deal to Enhance Cancer Drug Pipeline
Trendline Trendline
ABION's Preclinical Data Shows ABN202 Outperforms TROP2-Targeting ADCs in Cancer Treatment

ABION's Preclinical Data Shows ABN202 Outperforms TROP2-Targeting ADCs in Cancer Treatment

ABION's Preclinical Data Shows ABN202 Outperforms TROP2-Targeting ADCs in Cancer Treatment
Trendline Trendline
ABION's ABN202 Shows Promise in Overcoming Resistance in Cancer Treatment

ABION's ABN202 Shows Promise in Overcoming Resistance in Cancer Treatment

ABION's ABN202 Shows Promise in Overcoming Resistance in Cancer Treatment
Trendline Trendline
Gilead Sciences Expands Oncology Portfolio with $5 Billion Tubulis Acquisition

Gilead Sciences Expands Oncology Portfolio with $5 Billion Tubulis Acquisition

Gilead Sciences Expands Oncology Portfolio with $5 Billion Tubulis Acquisition
Trendline Trendline
Gilead Sciences Acquires Tubulis in $5 Billion Deal to Expand Oncology Portfolio

Gilead Sciences Acquires Tubulis in $5 Billion Deal to Expand Oncology Portfolio

Gilead Sciences Acquires Tubulis in $5 Billion Deal to Expand Oncology Portfolio
Trendline Trendline
Gilead Sciences Expands Oncology Pipeline with Tubulis Acquisition

Gilead Sciences Expands Oncology Pipeline with Tubulis Acquisition

Gilead Sciences Expands Oncology Pipeline with Tubulis Acquisition